Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

8.01
+0.40505.33%
Volume:1.99M
Turnover:15.64M
Market Cap:974.82M
PE:-19.27
High:8.15
Open:7.55
Low:7.45
Close:7.60
52wk High:8.78
52wk Low:2.36
Shares:121.78M
Float Shares:90.63M
Volume Ratio:1.71
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4155
EPS(LYR):-0.4698
ROE:-35.74%
ROA:-22.83%
PB:4.91
PE(LYR):-17.04

Loading ...

Company Profile

Company Name:
Trevi Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
33
Office Location:
195 Church Street,16th Floor,New Haven,Connecticut,United States
Zip Code:
06510
Fax:
- -
Introduction:
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Directors

Name
Position
David Meeker
Chairman and Director
Jennifer Good
President and Chief Executive Officer and Director and interim Principal Financial Officer
Anne VanLent
Director
Dominick Colangelo
Director
Edward Mathers
Director
Michael Heffernan
Director

Shareholders

Name
Position
Jennifer Good
President and Chief Executive Officer and Director and interim Principal Financial Officer
Farrell Simon
Chief Commercial Officer
James Cassella
Chief Development Officer
Thomas Sciascia
co-founder and Chief Scientific Officer